Drugs / Dextrose
last change 5 days ago re-read 2 minutes ago

Dextrose

targets TRPV1 via inhibition

Developed for
osteoarthritis, knee · carpal tunnel syndrome · frozen shoulder · chronic pain syndrome · temporomandibular joint disorder · epicondylitis · hypermobility syndrome · myofascial pain syndrome
+30 more · osteoarthritis, hand · rotator cuff syndrome · arthropathy · chronic kidney disease · chronic renal failure syndrome · Ehlers-Danlos syndrome, hypermobility type · end stage renal failure · gastroschisis · hypermobility spectrum disorder · hypoglycemia · intermediate coronary syndrome · interstitial cystitis · lumbar disk degenerative disorder · lumbar spinal stenosis · meralgia paresthetica · musculoskeletal system disorder · myocardial infarction · pes anserinus tendinitis or bursitis · plantar fasciitis · post-traumatic stress disorder · pulmonary immaturity · sciatica · subacute bursitis · symptomatic heart failure · tendinosis · type 2 diabetes mellitus · acute tubulointerstitial nephritis · enthesopathy · radial nerve lesion · ulnar neuropathy
Investigated by
Tri-Service General Hospital (TSGH) · London Health Sciences Centre Research Institute OR Lawson Research Institute of St. Joseph's · Mayo Clinic · University of Alexandria · Alexandria University · Christine M. Kleinert Institute for Hand and Microsurgery
+76 more · Hadassah Medical Organization · Hasanuddin University · National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK) · Taipei Medical University · University of Malaya · Yale University · Academic Pediatric Association · Ahi Evran University Education and Research Hospital · Ain Shams University · Aksaray University Training and Research Hospital · American Academy of Pediatrics · American Association of Orthopaedic Medicine · American Diabetes Association · Assiut University · Azienda Ospedaliera di Padova · Bakirkoy Dr. Dr. Sadi Konuk Research and Training Hospital · Bangladesh Medical University · Baxter Healthcare Corporation · British Columbia Cancer Agency · Bumi Herman · Cairo University · Cecilia Calvo · Chang Gung Memorial Hospital · Children's Hospital of Philadelphia · Dinara Zhumanbayeva · Dr Cipto Mangunkusumo General Hospital · Dr. Dean Reeves Clinic · First Affiliated Hospital, Sun Yat-Sen University · Fisiatria y Traumatología · Helena Hildenwall · Hospital Universitario La Paz · Istanbul Physical Medicine Rehabilitation Training and Research Hospital · Kamuzu University of Health Sciences · Karadeniz Technical University · Kleinert, Kutz and Associates · Makerere University · Manhattan Pain Medicine, PLLC · McGill University Health Centre/Research Institute of the McGill University Health Centre · Mexican Social Security Institute · Ministry of Health, Malaysia · Ministry of Science and Technology, Taiwan · National Center for Complementary and Integrative Health (NCCIH) · National Cheng-Kung University Hospital · National Defense Medical Center, Taiwan · National Health Research Institutes, Taiwan · National Heart, Lung, and Blood Institute (NHLBI) · National Taiwan University Hospital · National Yang Ming Chiao Tung University Hospital · Nourhan M.Aly · Ondokuz Mayıs University · Ordu University · Ospedali Riuniti Ancona · Penang Hospital, Malaysia · Reuth Rehabilitation Hospital · Rizki Darmawan · Rumah Sakit Umum Daerah Haji Provinsi Jawa Timur, Indonesia · Sequana Medical N.V. · Sheikh Zayed Medical College · Shin Kong Wu Ho-Su Memorial Hospital · Suez Canal University · Tanta University · The Cleveland Clinic · The Seekers Centre · Thomas Jefferson University · Tufts Medical Center · Tulane University · Universidad Nacional de Rosario · University Medical Centre Ljubljana · University at Buffalo · University of Arkansas · University of Kansas Medical Center · University of Pittsburgh · University of Saskatchewan · University of Targu Mures, Romania · all 82 on the full record

Regulatory milestones approvals, filings & regulatory actions · 3 recorded

MilestoneJurisdictionBrandIndicationDateSentence it was read from
Label expansion US (FDA) DEXTROSE 70% IN PLASTIC CONTAINER 2000-12-07 fda.gov
Label expansion US (FDA) DEXTROSE 50% 1998-11-23 fda.gov
Approved US (FDA) ALCOHOL 5% AND DEXTROSE 5% 1946-01-17 fda.gov

Trials 78 · started per year

today
US approved 1946
1
2
2
2
2
4
1
3
5
6
8
3
7
6
9
6
6
5
194419451946194719481949195019511952195319541955195619571958195919601961196219631964196519661967196819691970197119721973197419751976197719781979198019811982198319841985198619871988198919901991199219931994199519961997199819992000200120022003200420052006200720082009201020112012201320142015201620172018201920202021202220232024202520262027202820292030
PhaseRegistry idDatesIndicationSponsorStatusOutcome
Phase 03 trials
Phase 0 NCT04832009 May 2022 → Aug 2026 overdue hypertensive disorder University of Kansas Medical Center Recruiting No outcome recorded
Phase 0 NCT04945499 Jun 2019 → Jun 2022 Zhujiang Hospital Unknown No outcome recorded
Phase 0 NCT03801226 Dec 2018 → May 2019 symptomatic heart failure Yale University Completed No outcome recorded
Phase 14 trials
Phase 1 NCT05780086 Feb → Aug 2023 chronic kidney disease Mexican Social Security Institute Unknown No outcome recorded
Phase 1 NCT05185999 Oct 2022 → Oct 2023 chronic renal failure syndrome London Health Sciences Centre Research Institute OR Lawson Research Institute of St. Joseph's Completed No outcome recorded
Phase 1 NCT04640662 Feb 2020 → Jun 2021 tendinosis University of Malaya Completed No outcome recorded
Phase 1 NCT03205553 Feb → May 2018 gastroschisis University of Arkansas Terminated No outcome recorded
Phase 1/22 trials
Phase 1/2 NCT07688096 Jul 2026 → Sep 2027 expected Ehlers-Danlos syndrome, hypermobility type, chronic pain syndrome, hypermobility spectrum disorder, hypermobility syndrome Manhattan Pain Medicine, PLLC Not yet recruiting No outcome recorded
Phase 1/2 NCT06829030 Jul 2024 → Feb 2025 overdue Aksaray University Training and Research Hospital Enrolling by invitation No outcome recorded
Phase 27 trials
Phase 2 NCT07548047 Jun 2026 → Jun 2028 expected Thomas Jefferson University Not yet recruiting No outcome recorded
Phase 2 NCT06293885 Mar 2024 → Apr 2025 London Health Sciences Centre Research Institute OR Lawson Research Institute of St. Joseph's Unknown No outcome recorded
Phase 2 NCT05160532 Apr 2022 → May 2025 osteoarthritis, knee Mayo Clinic Completed No outcome recorded
Phase 2 NCT04557878 Oct 2020 → Apr 2021 temporomandibular joint disorder Nourhan M.Aly Completed No outcome recorded
Phase 2 NCT02796729 Oct 2016 → Dec 2018 metastatic malignant neoplasm in the brain British Columbia Cancer Agency Terminated No outcome recorded
Phase 2 NCT01897259 Mar 2012 → Jun 2019 epicondylitis Christine M. Kleinert Institute for Hand and Microsurgery Unknown No outcome recorded
Phase 2 NCT01285713 Sep 2010 → Aug 2011 Children's Hospital of Philadelphia Completed No outcome recorded
Phase 2/35 trials
Phase 2/3 NCT06859034 Mar → Sep 2025 overdue temporomandibular joint disorder Cairo University Not yet recruiting No outcome recorded
Phase 2/3 NCT05548738 Apr 2022 → Nov 2023 chronic pain syndrome Alexandria University Completed No outcome recorded
Phase 2/3 NCT04802785 Jun → Jul 2021 Dinara Zhumanbayeva Unknown No outcome recorded
Phase 2/3 NCT01210183 Jul 2010 → Dec 2013 osteoarthritis, knee Universidad Nacional de Rosario Completed No outcome recorded
Phase 2/3 NCT00674622 Sep 2007 → Oct 2010 epicondylitis University of Pittsburgh Completed No outcome recorded
Phase 35 trials
Phase 3 NCT05279937 Jun 2026 → Jun 2027 expected Ehlers-Danlos syndrome Tulane University Not yet recruiting No outcome recorded
Phase 3 NCT07102225 May 2025 → Sep 2026 expected osteoarthritis, knee Bangladesh Medical University Active not recruiting No outcome recorded
Phase 3 NCT06847594 Feb → Sep 2024 Ain Shams University Completed No outcome recorded
Phase 3 NCT04791202 Apr 2021 → Mar 2022 Christine M. Kleinert Institute for Hand and Microsurgery Unknown No outcome recorded
Phase 3 NCT00091507 Nov 2006 → Aug 2011 congestive heart failure, intermediate coronary syndrome, myocardial infarction Tufts Medical Center Completed No outcome recorded
Phase 417 trials
Phase 4 NCT07382596 May 2026 → Mar 2030 expected post-traumatic stress disorder Dr. Dean Reeves Clinic Recruiting No outcome recorded
Phase 4 NCT06726980 Jan 2025 → Jan 2026 overdue Assiut University Not yet recruiting No outcome recorded
Phase 4 NCT06349824 Oct 2023 → Mar 2024 carpal tunnel syndrome Sheikh Zayed Medical College Completed No outcome recorded
Phase 4 NCT05977985 Aug 2023 → Jul 2024 frozen shoulder University of Malaya Unknown No outcome recorded
Phase 4 NCT05918146 Jun 2023 → Jun 2024 subacute bursitis Taipei Medical University Unknown No outcome recorded
Phase 4 NCT05264727 May 2023 → Dec 2025 overdue obesity disorder, type 2 diabetes mellitus Mayo Clinic Active not recruiting No outcome recorded
Phase 4 NCT05721404 May 2023 → Apr 2027 expected First Affiliated Hospital, Sun Yat-Sen University Recruiting No outcome recorded
Phase 4 NCT05131269 Dec 2021 → May 2022 frozen shoulder Bumi Herman Completed No outcome recorded
Phase 4 NCT03693287 Jul 2021 → Aug 2023 pulmonary immaturity Ospedali Riuniti Ancona Unknown No outcome recorded
Phase 4 NCT04062838 Aug 2020 → Dec 2021 rotator cuff syndrome Hadassah Medical Organization Withdrawn No outcome recorded
Phase not applicable35 trials
NCT07498998 Jul → Aug 2026 overdue carpal tunnel syndrome Tanta University Not yet recruiting No outcome recorded
NCT06872645 Oct 2025 → Jun 2028 expected Yale University Recruiting No outcome recorded
NCT07559058 Oct 2025 → Jan 2026 frozen shoulder, rotator cuff syndrome Rizki Darmawan Completed No outcome recorded
NCT07479693 Jan → Aug 2025 hydrarthrosis, temporomandibular joint disorder Ondokuz Mayıs University Completed No outcome recorded
NCT06617065 Sep 2024 → Jan 2025 overdue chronic pain syndrome The Seekers Centre Active not recruiting No outcome recorded
NCT06165939 Jan → Dec 2024 frozen shoulder Tri-Service General Hospital (TSGH) Unknown No outcome recorded
NCT06165926 Jan → Dec 2024 frozen shoulder Tri-Service General Hospital (TSGH) Unknown No outcome recorded
NCT05984121 Aug → Dec 2023 plantar fasciitis Ahi Evran University Education and Research Hospital Completed No outcome recorded
NCT05966948 May → Sep 2023 obesity disorder, osteoarthritis, knee Rumah Sakit Umum Daerah Haji Provinsi Jawa Timur, Indonesia Completed No outcome recorded
NCT06301958 Jan 2023 → Aug 2024 arthropathy Chang Gung Memorial Hospital Unknown No outcome recorded
Also used as a comparator or background therapy in 62 trials
PhaseRegistry idDatesIndicationSponsorStatusOutcome
Phase 04 trials
Phase 0 NCT07296653 Comparator Dec 2025 → Dec 2026 expected National and Kapodistrian University of Athens Recruiting No outcome recorded
Phase 0 NCT04133922 Comparator Oct 2019 → Oct 2023 type 1 diabetes mellitus University of Virginia Withdrawn No outcome recorded
Phase 0 NCT03520569 Comparator Feb 2019 → Apr 2021 arterial disorder University of Virginia Completed No outcome recorded
Phase 0 NCT02982551 Background Jan 2016 → Dec 2017 University of Pittsburgh Withdrawn No outcome recorded
Phase 15 trials
Phase 1 NCT06592261 Background Sep 2024 → Aug 2026 overdue hyperinsulinism, obesity disorder Columbia University Recruiting No outcome recorded
Phase 1 NCT05724134 Background Aug 2023 → Sep 2025 NAFLD1, hyperinsulinism, obesity disorder, prediabetes syndrome Columbia University Completed No outcome recorded
Phase 1 NCT03095651 Background Apr 2017 → Jan 2018 type 1 diabetes mellitus, type 2 diabetes mellitus Merck Sharp & Dohme LLC Completed No outcome recorded
Phase 1 NCT02971202 Background Dec 2016 → Feb 2019 maturity-onset diabetes of the young type 2, type 1 diabetes mellitus Vanderbilt University Completed No outcome recorded
Phase 1 NCT02269735 Background Nov 2014 → Jul 2016 type 1 diabetes mellitus Merck Sharp & Dohme LLC Completed No outcome recorded
Phase 25 trials
Phase 2 NCT06911359 Comparator Mar 2025 → Dec 2026 expected osteoarthritis, knee David Grant U.S. Air Force Medical Center Recruiting No outcome recorded
Phase 2 NCT04603014 Background Jan 2021 → Dec 2026 expected end stage renal failure London Health Sciences Centre Research Institute OR Lawson Research Institute of St. Joseph's Active not recruiting No outcome recorded
Phase 2 NCT02632630 Comparator Mar 2016 → Feb 2018 nutritional deficiency disease London Health Sciences Centre Research Institute OR Lawson Research Institute of St. Joseph's Completed No outcome recorded
Phase 2 NCT01547364 Comparator Feb 2012 → Oct 2013 Smigel, Liza, M.D. Completed No outcome recorded
Phase 2 NCT01281761 Background Nov 2010 → Sep 2012 colorectal cancer Samsung Medical Center Completed No outcome recorded
Phase 2/33 trials
Phase 2/3 NCT02752308 Comparator Sep 2014 → Mar 2015 hypospadias Isfahan University of Medical Sciences Completed No outcome recorded
Phase 2/3 NCT02185729 Comparator Jun 2008 → Mar 2012 metabolic disease Emory University Completed No outcome recorded
Phase 2/3 NCT00835939 Comparator Sep 2007 → Jan 2010 enthesopathy, tendinosis University of Calgary Unknown No outcome recorded
Phase 37 trials
Phase 3 NCT06045013 Comparator Sep 2023 → Jan 2026 overdue carpal tunnel syndrome General and Veteran Hospital Croatian Pride Knin Recruiting No outcome recorded
Phase 3 NCT05326763 Comparator May 2021 → Dec 2022 epicondylitis Chen Yueh Unknown No outcome recorded
Phase 3 NCT02728037 Background Apr 2016 → Mar 2020 pelvis syndrome Queen's University Terminated No outcome recorded
Phase 3 NCT01909336 Comparator Jul 2013 → Feb 2014 Instituto Tecnologico y de Estudios Superiores de Monterey Completed No outcome recorded
Phase 3 NCT00632775 Comparator Dec 2007 → Sep 2012 The Hospital for Sick Children Completed No outcome recorded
Phase 418 trials
Phase 4 NCT07494084 Comparator Jul 2026 → Mar 2029 expected circadian rhythm sleep disorder, shift work type Washington State University Not yet recruiting No outcome recorded
Phase 4 NCT07283874 Comparator Dec 2025 → Dec 2026 expected carpal tunnel syndrome Assiut University Not yet recruiting No outcome recorded
Phase 4 NCT07124130 Comparator Sep 2025 → Mar 2026 overdue Eastern Virginia Medical School Recruiting No outcome recorded
Phase 4 NCT07105540 Comparator Aug 2025 → Feb 2026 carpal tunnel syndrome Ankara Etlik City Hospital Completed No outcome recorded
Phase 4 NCT06349265 Comparator Oct 2023 → Feb 2024 carpal tunnel syndrome Kastamonu University Completed No outcome recorded
Phase not applicable20 trials
NCT07564063 Comparator Jun → Dec 2026 expected Cairo University Not yet recruiting No outcome recorded
NCT07451561 Comparator Mar 2026 → Mar 2027 expected Sohag University Not yet recruiting No outcome recorded
NCT07524933 Comparator Jan → Jul 2026 overdue Antalya Training and Research Hospital Active not recruiting No outcome recorded
NCT07245121 Comparator Nov 2025 → Dec 2026 expected chronic pain syndrome, osteoarthritis, knee National and Kapodistrian University of Athens Recruiting No outcome recorded
NCT07241559 Comparator Nov 2025 → Apr 2026 overdue chronic pain syndrome Ankara City Hospital Bilkent Recruiting No outcome recorded

Evidence & citations 17 cited values

Every value below carries the sentence it was read from. 143 sources stand behind the page.

FieldValueCited text
Known as Dextrose “Intra-articular injection with 25% dextrose will be carried out with the following details: 5 mL of 40% dextrose, 2 mL of lidocaine, and 1 mL of aqua dest are inserted into the...” NCT04557943
135

“bolus of 1-3 IU/kg regular insulin together with 0.5-1 gm/kg dextrose followed by an intravenous infusion of 0.2 to 1 IU/kg/hr of regular insulin and a dextrose infusion will...” NCT07451561

“1.5 cc 30% dextrose solution and 1.5 cc 2 lidocaine mixture with a 25 gauge needle into the medial plantar region cc 2 lidocaine mixture will be made sterile with 3 cc 15% dextrose.” NCT05984121

“Prolotherapy group Patients in the prolotherapy group will receive a single 2 mL injection of 16.5% dextrose solution administered under ultrasound guidance.” NCT04640662

“Participants receive a glucose infusion consisting of 10% dextrose infused intravenously at a rate of 200 mg/m\^2/min for 20 hours.” NCT00753142

“Intravenous glucose will be "dextrose 50%", amino acids (AA) will be "Primene®" and lipids (FAT) will be "Clinoleic®".” NCT03693287

“Subjects participating in the prolotherapy group will recieve 1 cc 50% Dextrose and Sodium Morrhuate 1 cc injections.” NCT01897259

“Patients were infiltrated with 5cc of dextrose 15% at the lateral epicondyle according to the standard technique.” NCT04395417

“prior controlled study reported short-term pain relief after caudal epidural injection of 5% dextrose (D5W)” PMID 29883193 Jun 2018

“Intravenous sodium bicarbonate (130 mEq/L) in 4.35% dextrose at 3.5 ml/Kg over 1 hour pre-contrast” NCT00749827

“an Infusion of dextrose 20% supplemented with pottasium phosphate (30 mmol/L ) to be administered.” NCT02746432

“a titrating dose of 20% dextrose aiming to a blood glucose level of 4 - 5.5 mmol/l.” NCT01271140

“In one-liter: Dextrose 30% + 80 mEq Potassium Chloride + 50 units Regular Insulin” NCT00091507

dextrose plus hyaluronic acid injection, one time per week, for 3 weeks” NCT04165902

dextrose 20% supplemented with phosphate (30 mmol/L) will be infused.” NCT06126419

“500 ml of 10% dextrose in water administered over a 30-minute period” NCT04012138

“Injection of 15% dextrose with lidocaine at the lateral epicondyle” NCT00674622

“D1 Irinotecan 150-180mg/m2 + Dextrose 5% 500ml IV \[over 90min\]” NCT01281761

“Drug = prolotherapy (%15 dextrose solution) into hand joints” NCT03839108

“Chirocaine (%0.75) + Dextrose 40 mg+20 mcg fentanyl” NCT03956303

“30% dextrose water with 80 mmol/l of potassium” NCT01825720

“20 mL of 15% hypertonic dextrose solutions” NCT07355712

“The injectant is 5ml 5% dextrose solution.” NCT06161038

“normal saline, dextrose, lactated Ringer's” NCT02632630

“The injectant is 5ml 5% dextrose solution.” NCT05154695

“levobupivacaine plus 60 mg dextroseNCT01938755

Dextrose 13.5 g per os” NCT04802785

NCT04509440

NCT04832009

NCT06829030

NCT05160532

NCT02376218

NCT02752308

NCT06617065

NCT04206579

NCT01912807

NCT06847594

NCT07002892

NCT02796729

NCT02590081

NCT06349265

NCT02653092

NCT07124130

NCT05264727

NCT07283874

NCT05977985

NCT04680936

NCT00457873

NCT07548047

NCT07479693

NCT03520569

NCT06911359

NCT02809261

NCT05966948

NCT04014244

NCT04133922

NCT02185729

NCT06293885

NCT00774098

NCT07524933

NCT07559058

NCT05429827

NCT03238183

NCT04979273

NCT04958213

NCT02984098

NCT02331069

NCT02971202

NCT05177263

NCT04603014

NCT06872645

NCT05326763

NCT01210183

NCT02989675

NCT07564063

NCT02982551

NCT06301958

NCT05279937

NCT03095651

NCT06165926

NCT03801226

NCT07688096

NCT06165939

NCT01285713

NCT07503574

NCT07015450

NCT04821882

NCT04062838

NCT06592261

NCT07382596

NCT02888795

NCT02102243

NCT02476448

NCT05239091

NCT02269735

NCT04499911

NCT07245121

NCT05918146

NCT07428512

NCT02990962

NCT04178304

NCT01547364

NCT05721404

NCT01151605

NCT04791202

NCT06349824

NCT01934868

NCT07241559

NCT04264000

NCT04557878

NCT07494084

NCT07498998

NCT00632775

NCT03400631

NCT04150978

NCT05131269

NCT00220766

NCT04949139

NCT06036823

NCT04941118

NCT05185999

NCT02492945

NCT07102225

NCT06045013

NCT07296653

NCT07105540

NCT07020455

NCT00835939

NCT01688674

NCT00685880

NCT04492150

NCT06726980

NCT05780086

NCT01909336

NCT02728037

NCT06859034

Known as 20% D-glucose (aq) 20% D-glucose (aq) (D20W) will be administered to counteract hypoglycemia or strongly downward blood glucose trends, as needed.” NCT05724134
Known as 5% Dextrose “500 ml of 5% Dextrose administered to a peripheral vein.” NCT04150978
Known as 5% dextrose injection “Drug: 5% dextrose injectionNCT07241559
Known as d-glucose “Prolo Group: All participants will receive 15% dextrose (D-glucose) with 1% lidocaine.” NCT07296653
3

“dextrose, also known as d-glucoseNCT04821882

NCT05724134

NCT04945499

Known as D10W “dextrose 10% (D10W ®) infusion” NCT00774098
Known as D20W “20% D-glucose (aq) (D20W) will be administered to counteract hypoglycemia or strongly downward blood glucose trends, as needed.” NCT05724134
Known as D5W “perineural injection of peripheral nerves, plexi, or sympathetic ganglia with dextrose 5% in water (D5W), has performed well empirically in the treatment of post-traumatic...” NCT07382596
4

“The effect of injecting 1 mL each of normal saline and 5% dextrose in water (NS and D5W) on muscle twitch was investigated at all 20 needle insertion sites.” PMID 15138901 May 2004

“Perineural injection with 5% dextrose (D5W).” NCT07498998

“Drug: Dextrose 5% (D5W)” NCT02331069

“5% dextrose (D5W)” PMID 31368191 Aug 2019

Known as Dextrose 20 % in Water “Drug: Dextrose 20 % in WaterNCT04133922
Known as Dianeal PD-2 ClinicalTrials.gov intervention name — accepted as the source's own label NCT04887480
Known as Glucose “Using Dextrose (Glucose) Gel to Reverse Neonatal Hypoglycemia.” PMID 28764827 Jul 2017
Known as perineural dextrose injection perineural dextrose injectionNCT07002892
Known as Peritoneal Dialysis Solution/Dextrose ClinicalTrials.gov intervention name — accepted as the source's own label NCT03205553
Action Inhibit “5% Dextrose could decrease the release of CGRP and substance P to reduce the nerve inflamation.” NCT02809261
Modality Diagnostic / imaging agent “using d-glucose as an contrast agent on CEST MR Imaging” NCT04945499
Route Intravenous Intravenous solution” NCT00091507
Target TRPV1 “Perineural prolotherapy (glucose concentration DW 5%) seems to exert therapeutic effects by inhibiting the activation of the TRPV1 pain receptor located at the terminals of...” NCT07245121